"Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials’’ was published in Molecular Therapy Methods & Clinical Development Assessing anti-AAV antibodies is an important consideration prior to Gene Therapy administration. This paper explores and discusses the clinical rationale for using centralized TI assays in Pfizer’s three phase 3 rAAV gene therapy clinical trials. https://lnkd.in/eUBNsYdv #rAAV #GeneTherapy
